Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 Fatty Acids for MDD With High Inflammation
NCT02553915Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eicosapentaenoic acid in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Started Dec 2015; status: completed.
02
Drugs
eicosapentaenoic acid
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02553915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553915.